ea0077oc6.1 | Thyroid | SFEBES2021
Cheetham Tim
, Cole Michael
, Abinun Mario
, Alalhabadia Amit
, Barratt Tim
, Davies Justin
, Dimitri Paul
, Drake Amanda
, Mohamed Zainaba
, Murray Robert
, Steele Caroline
, Zammitt Nicola
, Carnell Sonya
, Prichard Jonathan
, Watson Gillian
, Hambleton Sophie
, Matthews John
, Pearce Simon
Objective: Remission rates in young people with GravesÂ’ hyperthyroidism are <25% after a 2-yr course of thionamide antithyroid drug (ATD). Immunomodulatory agents might improve outcome by facilitating immune tolerance. We explored whether rituximab (RTX) would increase remission rates when administered with a short course of ATD.Design: This was an open label multi-centre single arm phase 2 trial in newly presenting young people (12-20y) with Gr...